Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.
- Published In:
- Nature reviews. Endocrinology, 21(8), 482-494 (2025)
- Authors:
- Walker, Christopher S(3), Aitken, Jacqueline F, Vazhoor Amarsingh, Greeshma, Zhang, Shaoping, Cooper, Garth J S
- Database ID:
- RPEP-13964
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13964APA
Walker, Christopher S; Aitken, Jacqueline F; Vazhoor Amarsingh, Greeshma; Zhang, Shaoping; Cooper, Garth J S. (2025). Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.. Nature reviews. Endocrinology, 21(8), 482-494. https://doi.org/10.1038/s41574-025-01125-9
MLA
Walker, Christopher S, et al. "Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.." Nature reviews. Endocrinology, 2025. https://doi.org/10.1038/s41574-025-01125-9
RethinkPeptides
RethinkPeptides Research Database. "Amylin: emergent therapeutic opportunities in overweight, ob..." RPEP-13964. Retrieved from https://rethinkpeptides.com/research/walker-2025-amylin-emergent-therapeutic-opportunities
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.